Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen-based DC Vaccine + Microwave Ablation for HCC
NCT03674073Phase 1Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2018
- Primary completion
- Oct 2020
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Adverse Events at 1 year. Started Oct 2018; status: completed.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03674073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03674073.